


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Kjell G.E. Bäckström et al.
 Serial No. : 08/736,267
 Filed : October 24, 1996
 Title : COMPOSITIONS FOR INHALATION

Art Unit : 1653
 Examiner : D. Lukton

Commissioner for Patents
 Washington, D.C. 20231



RESPONSE

RECEIVED

JAN 22 2001

TECH CENTER 1600/2800

36/G
 1/25/01

In response to the action mailed July 14, 2000, please consider the following amendments and remarks.

In the Specification:

Replace the paragraph at page 11, lines 18-31, with the following paragraph.

G! Phospholipids were also tested as enhancers. It was found that a single-chain phospholipid (lysophosphatidylcholine) was an effective enhancer, while one double-chain phospholipid (didecanoylphosphatidylcholine) was not. This may be explained by the fact that the double-chain phospholipid is much less soluble in water than its single-chain counterpart; however, it is reasonable to expect that double-chain phospholipids of shorter chain length, having greater water solubility than their longer chain counterparts, will be of use as enhancers in the present invention so that both single- and double-chain phospholipids may be used.

In the Claims:

Replace the claims as follows.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

January 12, 2001
 Date of Deposit

Jeanine Mecherkany
 Signature

Jeanine Mecherkany
 Typed or Printed Name of Person Signing Certificate

01/25/2001 6TRAMMEL 00000004 061050 08736267

01 FC:103 288.00 CH
 02 FC:102 80.00 CH